ZURA BIO LIMITED Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
ZURA BIO LIMITED (ZURA) reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$50.53 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2026-08-11
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $24.17M, a 38.85% increase year-over-year.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$24.22M.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$17.18M.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$51.44M.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for fiscal 2025 was -$68.65M.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for fiscal 2024 was -$52.40M.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$60.56M, a 1806.42% decline from fiscal 2022.
- ZURA BIO LIMITED net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was $3.55M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 1 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 2 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 4 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 5 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 7 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 7 month as first filed | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 8 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 10 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 11 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $24.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$50.53K 10-Q · filed 2026-08-11 | -$17.23M derived: sum of 3 quarters · filed 2026-08-11 | -$68.67M derived: sum of 4 quarters · filed 2026-08-11 | ||||||||||
| 2026-03-31 | -$24.22M 10-Q · filed 2026-05-07 | -$41.40M derived: sum of 2 quarters · filed 2026-05-07 | -$92.84M derived: sum of 3 quarters · filed 2026-05-07 | -$75.43M derived: sum of 4 quarters · filed 2026-08-11 | ||||||||||
| 2025-12-31 | -$17.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$68.62M derived: sum of 2 quarters · filed 2026-03-19 | -$51.21M derived: sum of 3 quarters · filed 2026-08-11 | -$68.65M 10-K · filed 2026-03-19 | ||||||||||
| 2025-09-30 | -$51.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$34.03M derived: sum of 2 quarters · filed 2026-08-11 | -$51.48M 10-Q · filed 2025-11-13 | -$65.10M derived: sum of 4 quarters · filed 2026-08-11 | ||||||||||
| 2025-06-30 | $17.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$33.44K 10-Q · filed 2026-08-11 | -$33.44M 10-Q · filed 2025-08-14 | -$13.66M derived: sum of 3 quarters · filed 2026-08-11 | -$34.36M derived: sum of 4 quarters · filed 2026-08-11 | |||||||||
| 2025-03-31 | -$17.44M 10-Q · filed 2026-05-07 | -$31.07M derived: sum of 2 quarters · filed 2026-05-07 | -$51.77M derived: sum of 3 quarters · filed 2026-05-07 | -$62.10M derived: sum of 4 quarters · filed 2026-05-07 | ||||||||||
| 2024-12-31 | -$13.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$34.33M derived: sum of 2 quarters · filed 2026-03-19 | -$44.66M derived: sum of 3 quarters · filed 2026-03-19 | -$52.40M 10-K · filed 2026-03-19 | ||||||||||
| 2024-09-30 | -$20.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$31.03M derived: sum of 2 quarters · filed 2025-11-13 | -$38.78M 10-Q · filed 2025-11-13 | -$47.25M derived: sum of 4 quarters · filed 2025-11-13 | ||||||||||
| 2024-06-30 | -$10.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$18.08M 10-Q · filed 2025-08-14 | -$26.55M derived: sum of 3 quarters · filed 2025-08-14 | -$34.82M derived: sum of 4 quarters · filed 2025-08-14 | ||||||||||
| 2024-03-31 | -$7.75M 10-Q · filed 2025-05-08 | -$16.22M derived: sum of 2 quarters · filed 2025-05-08 | -$24.49M derived: sum of 3 quarters · filed 2025-05-08 | -$58.52M derived: sum of 4 quarters · filed 2025-05-08 | ||||||||||
| 2023-12-31 | -$8.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$16.74M derived: sum of 2 quarters · filed 2025-03-25 | -$50.77M derived: sum of 3 quarters · filed 2025-03-25 | -$60.56M 10-K · filed 2025-03-25 | ||||||||||
| 2023-09-30 | -$8.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$42.30M derived: sum of 2 quarters · filed 2024-11-07 | -$52.09M 10-Q · filed 2024-11-07 | -$51.42M derived: sum of 4 quarters · filed 2024-11-07 | ||||||||||
| 2023-06-30 | -$34.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$43.82M 10-Q · filed 2024-08-13 | -$43.15M derived: sum of 3 quarters · filed 2024-08-13 | -$42.69M derived: sum of 4 quarters · filed 2024-08-13 | ||||||||||
| 2023-03-31 | -$9.79M 10-Q · filed 2024-05-09 | -$9.12M derived: sum of 2 quarters · filed 2024-05-09 | -$8.66M derived: sum of 3 quarters · filed 2024-05-09 | -$6.39M derived: sum of 4 quarters · filed 2024-05-09 | ||||||||||
| 2022-12-31 | $672.22K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.13M derived: sum of 2 quarters · filed 2023-03-28 | $3.40M derived: sum of 3 quarters · filed 2023-03-28 | -$27.33M 10-K · filed 2024-03-28 | $3.55M 10-K · filed 2023-03-28 | |||||||||
| 2022-09-30 | $458.47K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $2.73M derived: sum of 2 quarters · filed 2022-11-14 | -$9.85M 10-Q · filed 2023-11-13 | $2.88M 10-Q · filed 2022-11-14 | ||||||||||
| 2022-06-30 | $2.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$8.74M 10-Q · filed 2023-08-14 | $2.42M 10-Q · filed 2022-08-12 | |||||||||||
| 2022-03-31 | -$7.82M 10-Q · filed 2023-05-12 | $147.86K 10-Q · filed 2022-05-13 | ||||||||||||
| 2021-12-31 | $6.85M 10-K · filed 2023-03-28 | |||||||||||||
| 2021-09-30 | $5.73M 10-Q · filed 2022-11-14 | $6.03M 10-Q · filed 2021-11-19 | ||||||||||||
| 2021-06-30 | -$52.18K 10-Q · filed 2022-08-12 | |||||||||||||
| 2021-03-31 | -$33.04K 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |